The research team followed 156 adults who developed invasive pneumococcal disease and required hospital care in Region Västra Götaland, Sweden, between 2018 and 2023. The median age of the patients was 70 years, a demographic in which both pneumococcal disease and blood malignancies become progressively more common. To determine whether the severe infection was merely bad luck or a signal of hidden vulnerability, the researchers performed detailed immunological workups. They measured antibody levels to detect deficiencies in humoral immunity, and they tested for the presence of M protein, a monoclonal immunoglobulin that serves as a well-established risk marker for blood cancer. A control group of 64 individuals, matched for age and sex but without invasive pneumococcal disease, provided a baseline for comparison.

The results were striking. Among the patients with invasive pneumococcal disease, one in four had M protein detectable in their blood. Monoclonal gammopathy of this kind can occur in established blood cancers, but it is also found in precursor states, conditions that do not yet meet the criteria for malignancy but can, in some patients, progress toward cancer over time. The examinations prompted by the study led to seven patients receiving a diagnosis of blood cancer, while another twelve were diagnosed with a precursor condition that may, in some cases, evolve into malignancy. In a group of just over 150 patients admitted for a severe bacterial infection, that represents a meaningful yield of previously silent disease.

The immune assessments also uncovered antibody deficiencies. Eight patients in the pneumococcal disease group were found to have immunodeficiency, and in seven of them, clinicians were able to start preventive treatment aimed at protecting against future severe infections. Such treatments can include replacement immunoglobulin therapy and tailored vaccination strategies, interventions that can substantially reduce the risk of recurrent invasive disease. By contrast, these abnormalities were considerably less common in the matched control group, reinforcing the idea that invasive pneumococcal infection is not randomly distributed but clusters in people whose immune surveillance is compromised.

The biological logic behind these findings is straightforward once the mechanics of pneumococcal immunity are considered. Streptococcus pneumoniae is an encapsulated bacterium, and its polysaccharide capsule is the principal target of protective antibodies. Clearance of the organism depends heavily on opsonization, the process by which antibodies coat the bacterium and mark it for destruction by phagocytic cells. People with low antibody levels, whether from a primary immunodeficiency or from the antibody-producing B-cell disorders that underlie many blood cancers, are therefore structurally less able to contain the bacterium when it colonizes the respiratory tract. What would be a mild or localized infection in an immunocompetent adult can become a systemic, hospital-requiring illness in someone whose humoral immunity is impaired.

M protein, the marker at the center of the study, is a monoclonal immunoglobulin produced by a single expanded clone of plasma cells or B cells. Its presence in the blood is the hallmark of a spectrum of disorders ranging from the benign-appearing monoclonal gammopathy of undetermined significance to smoldering and symptomatic myeloma. Because monoclonal gammopathies are common in older populations and often remain asymptomatic for years, most are discovered incidentally or not at all. The Gothenburg study suggests that severe pneumococcal disease may function as a clinical flag: when an older adult presents with invasive infection, the probability of finding an underlying monoclonal disorder is high enough that targeted testing could be worthwhile.

Currently, according to the researchers, these tests are not routinely performed after a severe pneumococcal infection. Tor Härnqvist, a doctoral student at the University of Gothenburg and an infectious disease physician at NU Hospital Group, and one of the lead authors of the study, points to the consequence of that gap. “Currently, these tests are not routinely performed after a severe pneumococcal infection. As a result, we may miss patients with undiagnosed blood cancer or immunodeficiency and therefore missing the opportunity to initiate treatment,” he says. The missed opportunity cuts in two directions: blood cancers such as myeloma are generally more treatable when identified before organ damage accumulates, and immunodeficiencies can be mitigated with preventive measures before the next invasive infection occurs.

The study carries implications for vaccination policy as well. Karin Bergman, a doctoral student in the same research group and an infectious disease physician at Södra Älvsborg Hospital, examined how the pneumococcal bacteria causing severe disease have shifted since the pneumococcal conjugate vaccine was introduced into the Swedish childhood vaccination program. Her analysis, part of a doctoral thesis she will soon defend at the University of Gothenburg, shows that the bacterial serotypes covered by the childhood vaccine have decreased sharply in circulation, but they have largely been replaced by other serotypes against which the childhood vaccine offers no protection. This serotype replacement is a well-documented ecological consequence of conjugate vaccination: eliminating vaccine-targeted strains from nasopharyngeal carriage opens ecological space for non-vaccine strains to colonize and spread.

Crucially, the serotypes now driving invasive disease in adults disproportionately affect older adults and individuals with underlying conditions, particularly cancer and compromised immune systems. This creates an uncomfortable alignment: the very populations most vulnerable to severe pneumococcal infection are those most likely to harbor undiagnosed blood cancer or antibody deficiency, and the circulating bacterial strains are precisely those that exploit gaps in adult immunity. “The results show that recommendations on pneumococcal vaccines for adults need to take into account which vaccines are used in children and which bacterial serotypes subsequently circulate in the community,” says Bergman. In other words, adult immunization strategy cannot be designed in isolation from the pediatric program, because the two are epidemiologically linked through the shifting serotype landscape.

Taken together, the findings support a concrete change in clinical practice. The researchers argue that screening for M proteins and antibody levels should be considered in adults who experience invasive pneumococcal disease, since the infection can reveal previously undiagnosed blood cancer and immunodeficiency. Such screening would involve relatively simple blood tests: quantitative measurement of serum immunoglobulins to identify antibody deficiencies, and protein electrophoresis or equivalent methods to detect monoclonal immunoglobulins. For a patient population that is already hospitalized and undergoing extensive workup, the incremental burden would be modest, while the potential benefit, catching a blood cancer or an immune deficiency that would otherwise remain hidden until it caused further harm, could be substantial. As populations age and serotype replacement continues to reshape pneumococcal epidemiology, the severe pneumonia that lands an older adult in the hospital may increasingly deserve to be read not only as an infection, but as a message from the immune system itself.

Subject of Research: Invasive pneumococcal disease as a marker of undiagnosed blood cancer and immunodeficiency in adults

Article Title: Pneumonia can reveal undiagnosed blood cancer

Article References: Pneumonia can reveal undiagnosed blood cancer. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: pneumococcal disease, pneumonia, blood cancer, M protein, immunodeficiency, monoclonal gammopathy, Streptococcus pneumoniae, antibody deficiency, pneumococcal vaccine, serotype replacement, University of Gothenburg, Scientific Reports

The research team, led by Joon Young Song of Korea University College of Medicine together with colleagues from Seoul National University, IQVIA and Merck, set out to quantify a gap that has long frustrated epidemiologists in the region. Reliable information on how pneumococcal disease affects adults in South Korea, and on whether vaccination programs have altered that picture, has been limited. To fill it, the investigators turned to one of the most powerful tools available in modern health research: a nationwide claims database covering virtually the entire population. They identified every hospitalization episode among adults aged 18 and older coded as invasive pneumococcal disease or pneumonia between 1 January 2010 and 31 December 2019, using the Korean version of the International Classification of Diseases to flag cases.

The study window was deliberately split around the 2014 vaccine rollout. Hospitalizations from 2010 to 2013 served as the pre-vaccination baseline, while those from 2015 to 2019 captured the post-introduction era, with the transition year excluded to allow the program to take hold. Rather than simply comparing average rates between the two periods, the researchers applied interrupted time series analysis, a statistical technique that separates an abrupt change in the level of a trend from a gradual change in its slope. Results were expressed as incidence rate ratios, with a value above 1 signaling an increase and a confidence interval crossing 1 indicating statistical uncertainty.

Over the full ten years, the database yielded 1,682 hospitalization episodes of invasive pneumococcal disease and 8,635 episodes of pneumonia among adults. Those raw counts translate into overall incidence rates of 0.4 episodes per 100,000 person-years for invasive disease and 2.1 per 100,000 person-years for pneumonia. Behind those averages lay a stark mortality gradient: 14.9 percent of adults hospitalized with invasive pneumococcal disease died, compared with 3.0 percent of those admitted with pneumonia. The burden was consistently concentrated among people aged 65 and older, the group in which pneumococcal infection most often turns fatal.

The interrupted time series results told two very different stories. For invasive pneumococcal disease, neither the level nor the slope of incidence changed significantly after the childhood program began. The level ratio was 1.26 with a 95 percent confidence interval of 0.99 to 1.59, just shy of conventional significance, and the slope ratio of 0.97, with an interval of 0.93 to 1.01, offered no evidence of a declining trend. In plain terms, the feared invasive infections, which include bacteremia and meningitis, neither dropped as herd-effect optimists might have hoped nor surged in any statistically convincing way. The adult burden simply persisted.

Pneumonia told a more surprising tale. The level of pneumonia incidence in the post-vaccination period was significantly higher than before, with an incidence rate ratio of 1.92 and a confidence interval of 1.51 to 2.42, meaning the post-program level was nearly double the baseline. The slope, however, was statistically flat, at 1.02 with an interval of 1.00 to 1.04, indicating that rates were not climbing year over year but had shifted upward as a step. The economic dimension followed the same pattern: the average total direct cost per pneumonia episode rose from 3.1 million Korean Won before the program to 4.1 million Won after it, an increase that ripples through a national health system when multiplied across thousands of admissions.

Why would a vaccine that protects children appear to coincide with more adult pneumonia? The authors are careful to avoid overinterpreting the association, and they point to several plausible explanations. Increased surveillance and heightened diagnostic awareness, particularly around respiratory illness, may have driven more hospitalizations to be coded and counted as pneumonia in the later period, inflating apparent incidence without a true rise in disease. Changes in coding practice, an aging population and shifting healthcare-seeking behavior could all contribute. It is also worth noting that pneumonia is a clinically broad category: many pneumonias in adults are not caused by pneumococcus at all, so a vaccine targeting one bacterium would not be expected to reverse trends driven by viruses and other pathogens.

The stability of invasive pneumococcal disease is equally instructive. Indirect, or herd, protection from childhood conjugate vaccination has been documented in several high-income countries, where declines in vaccine-type invasive disease among adults followed pediatric immunization. But the magnitude of that effect depends on how much of adult carriage and disease is caused by the strains covered by the vaccine, on how quickly non-vaccine strains fill the vacated ecological niche, and on adult vaccination coverage with the older polysaccharide vaccine, PPSV23, which South Korea has also deployed in older adults. The new study cannot disentangle these forces, but its results suggest that in the South Korean setting, the indirect benefit to adults from PCV13 in children was not strong enough to bend the invasive disease curve within five years.

The study comes with strengths and caveats that readers should weigh. Its great advantage is scale: a population-based database spanning a full decade, capturing hospitalizations across the entire country rather than a sample of sentinel hospitals. Its limitations are those inherent to claims data. Case identification relied on diagnostic codes rather than bacterial culture or polymerase chain reaction confirmation, so some episodes coded as pneumonia may not have been pneumococcal, and some true pneumococcal pneumonias may have been missed. The study was funded by Merck Sharp & Dohme, a subsidiary of Merck & Co., with study activities contracted to IQVIA, and several authors are employees or paid consultants of those companies, relationships disclosed in the publication. The descriptive design also means the analysis shows temporal association, not causation.

For policymakers, the message is less a verdict on PCV13 than a reminder that childhood immunization is not a complete answer for adult respiratory disease. The authors conclude that the incidence of invasive pneumococcal disease in South Korean adults remained stable while the incidence and economic burden of pneumonia increased after the vaccine entered the childhood program, and that vaccine use alongside factors such as increased surveillance may explain the observed results. As newer, higher-valency conjugate vaccines reach adult immunization schedules worldwide, studies like this one underscore the need for direct adult vaccination strategies, robust surveillance that can distinguish pneumococcal from non-pneumococcal pneumonia, and continued economic evaluation of who bears the cost when prevention falls short. The decade of Korean data suggests that protecting the oldest adults may require protecting them directly.

Subject of Research: Impact of childhood PCV13 vaccination on hospitalized adult pneumococcal disease in South Korea

Article Title: Association between introduction of 13-valent pneumococcal conjugate vaccine and burden of hospitalized adult pneumococcal disease in South Korea – a population-based retrospective database study

Article References: Song, J. Y., Choi, E. H., Choe, Y. J., Yeo, S.-H., Patel, D., Lim, C. T. K., Lee, Y. E., Yamada, E., & Sukarom, I. (2026). Association between introduction of 13-valent pneumococcal conjugate vaccine and burden of hospitalized adult pneumococcal disease in South Korea – a population-based retrospective database study. BMC Public Health. https://doi.org/10.1186/s12889-026-29058-6

Image Credits: AI Generated

DOI: 10.1186/s12889-026-29058-6

Keywords: pneumococcal disease, PCV13, pneumonia, vaccination, herd immunity, South Korea, epidemiology, invasive pneumococcal disease, healthcare costs, public health, National Health Information Database, interrupted time series